Remternetug  (Synonyms: LY3372993)

Remternetug (LY3372993) is a monoclonal antibody that targets pyroglutamylated amyloid β fibrils (N3pG-Aβ). Remternetug specifically binds to N3pG-Aβ, thereby clearing amyloid plaques in the brain and reducing amyloid burden. Remternetug can be used in research related to Alzheimer's disease^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

Amyloid Beta/Aβ

For mild cognitive impairment models, the single effective dose of LY3372993 ranges from 250 to 2800 mg (intravenous or subcutaneous injection), and the multiple effective dose ranges from 700 to 1400 mg (intravenous or subcutaneous injection), with a maximum treatment duration of 61 weeks^[3][4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

351  [NCBI]

P05067

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.916 kDa

2571940-41-3

Liquid

Colorless to light yellow

[Remternetug]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Flow cytometric analysis of 1X10⁶ HUVEC cells with Remternetug (HY-P990078, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Neațu M, et al. Monoclonal antibody therapy in Alzheimer’s disease[J]. Pharmaceutics, 2023, 16(1): 60.

  [2]. Panza F, et al. Successes and failures: the latest advances in the clinical development of amyloid-β-targeting monoclonal antibodies for treating Alzheimer's disease. Expert Opin Biol Ther. 2025;25(3):275-283.  [Content Brief]

  [3]. Eden A B. Drug Discovery for Alzheimer’s Disease Targeting the Transmembrane Domain of Amyloid Precursor Protein (APPTM)[M]. Rensselaer Polytechnic Institute, 2022.

  [4]. Noorda K, Noorda K, Sabbagh M N, et al. Amyloid-directed antibodies: past, present, and future[J]. Journal of Alzheimer’s Disease, 2024, 101(s1): S3-S22.